

Bank of America Merrill Lynch Global Healthcare Conference

September 14, 2011
London



Forward Looking Statement


This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2010, and subsequent SEC filings.




Leading National Lab Provider

- Fastest growing national lab
- \$55 billion market
- Clinical, Anatomic and Genomic Testing
- Serving clients in all 50 states and Canada
- Foremost clinical trials testing business



Laboratory Testing




Source: Deloitte (OAML)

Valuable Service

- Small component of total cost influences large percentage of clinical decisions
- Screening, early detection, and monitoring reduce downstream costs
- Companion diagnostics improve drug efficacy and reduce adverse drug effects


2010 Projected US Health Care Spend \$2.6 Trillion



Source: Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group; and U.S. Department of Commerce, Bureau of Economic Analysis and U.S. Bureau of the Census, and company estimates.

Growth Drivers

- Aging population
- Industry consolidation
- Advances in genomics
- Pharmacogenomics/
companion diagnostics
- Cost pressures




Source: CDC National Ambulatory Medical Care Survey and Company Estimates

Opportunity to Take Share

- Approximately 5,000 independent labs
- Less efficient, higher cost competitors

\$55 Billion US Lab Market




Source: Washington G-2 Reports and Company estimates

Diversified Payor Mix

- No customer > 9% of revenue
- Limited government exposure


LabCorp U.S. Payor Mix
% of revenue, 2010



Diversified Test Mix

With Genzyme GeneticsSM* acquisition, esoteric testing comprises approximately 40% of revenue

LabCorp U.S. Test Mix
% of revenue, 2010



*GENZYME GENETICSSM and its logo are trademarks of Genzyme Corporation and used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of LabCorp, under license. Esoterix Genetic Laboratories and LabCorp are operated independently from Genzyme Corporation.


Mission Statement

We Will Offer The Highest Quality
Laboratory Testing and Most
Compelling Value to Our
Customers

We Will Execute This Mission
Through Our **Five Pillar Strategy**




**Deploy Cash to Enhance
Footprint and Test Menu
and to Buy Shares**



Cash Flow


- 6-year FCF CAGR of 9.4%
- Strategic acquisitions
- \$2.0 B+ share repurchase over last three years



Note: \$ in millions and Free Cash Flow is a non-GAAP metric

Free Cash Flow Per Share


- 6-year FCF Per Share CAGR of 16.1%
- FCF Yield ranged from approximately 8% to 10% in 2010



Note: Free Cash Flow Per Share and Free Cash Flow Yield are non-GAAP metrics
FCF Yield range noted above was calculated using trailing twelve month Free Cash Flow, weighted average diluted share counts and closing stock prices during 2010

Scale and Scope

- National infrastructure
- Broad test offering
- Managed care contracts
- Economies of scale



● Patient Service Centers*

● Primary LabCorp Testing Locations*

● Esoteric Lab Locations

(CET, CMBP, Dianon, Esoterix, Monogram Biosciences, NGI, OTS, US Labs, Viomed)

Key Uses of Cash

- **Acquisitions**
 - Genzyme Genetics
 - Westcliff (LabWest, Inc)
 - DCL
- **Share Repurchase**
 - \$337.4 million in 2010
 - \$325.5 million in first half of 2011

genzyme
Genetics


LabWest INC
A LabCorp Company

The DCL logo features a large, light gray stylized '@' symbol in the background. Overlaid on the right side of the '@' is the text 'DCL' in a bold, black, sans-serif font. Below 'DCL' is the text 'Medical Laboratories' in a smaller, black, sans-serif font. At the bottom is the text 'A LabCorp Company' in an even smaller, black, sans-serif font.

DCL
Medical Laboratories
A LabCorp Company

Acquisition Rationale

- Creates the premier genetics and oncology business in the industry
- Builds on our strategy of leadership in personalized medicine
- Generates revenue opportunities
 - Selling LabCorp's test menu to Genzyme Genetics accounts
 - Selling Genzyme Genetics' test menu to LabCorp accounts
 - Genzyme Genetics customer access to LabCorp's convenient PSC network
 - Expanded use of genetic counselors
- Creates cost synergies
 - Logistics
 - Specimen collection
 - G&A
 - Facility overlap




- Preconception
- Pre- and post-natal
- Identification of disease carriers
- Identification of disease predisposition
- Diagnosis of genetically caused or influenced conditions (eg, developmental delay)
- Disease prognosis and treatment (especially cancer)



Five Pillar Strategy—Pillar One **Importance of Oncology**

- More sophisticated methods of cancer testing complement traditional biopsies
- Value of diagnostics for disease prognosis, and monitoring of progression and recurrence
- Critical role of testing in therapy selection




**Enhance IT Capabilities
To Improve Physician
and Patient Experience**



Intuitive Order Entry

- **Streamlined Ordering**
Provider, Diagnosis, Test and Collection information are all displayed in a single screen
- **Requisition and Account Logic**
Automatically generates requisitions with appropriate account numbers
- **Key Time-saving Features**
 - Send to PSC
 - Standing orders
 - Electronic add-on testing
 - User-defined pick lists



LabCorp Beacon

Welcome, user@domain.com | My Settings | Account Settings | Notifications | Help | Log Out

Home Results **Orders** Patients Trends

Orders / New Order

VISIT DATE: 04/26/10 ORDERED BY: Dr. AnyProvider STATUS: --

Patient, Anyname

GENDER: Male D.O.B.: 02/14/1932 AGE: 64 yrs NPI: 0000000000 PHONE: 000-000-0000 BILL METHOD: Medicare

Patient Visit Information [Edit](#)

PROVIDER LOCATION	PATIENT CLASSIFICATION Type
Medical Center West (000-000-0000)	NP
Dr. AnyProvider	Medical Center West, Medical Center East, Medical Center North 0000000000

Diagnosis Codes [Edit](#)

DIAGNOSIS CODE	DIAGNOSIS DESCRIPTION
122.40	Echinococcus granulosus infection unspecified
128.90	Helminth infection unspecified
393.00	Chronic rheumatic pericarditis

Tests and Panels [Edit](#)

TEST CODE	TEST NAME	SPECIMEN TYPE	OPT CODES	SYNONYMS
005009	Complete Blood Count (CBC) With Differential (Details)	Whole Blood	85025	CBC
Instructions: Maintain specimen at room temperature up to 24 hours. Refrigerate up to 48 hours.				
322758	Basic Metabolic Panel (B) (Details)	Serum (preferred) or plasma	80048	BMP Basic Metabolic Panel
235010	Lipid Panel With LDL:HDL Ratio (Details)	Serum (preferred) or plasma	80061	


Requisitions and Specimen Collection

Cancel **Save Order** **Collect & Send**

LabCorp 2011-15 Laboratory Corporation of America® Holdings. All Rights Reserved. Privacy Statement

Unified Results

- **Centralizes Lab Connectivity**
View lab reports from DIANON Systems, Esoterix, LabCorp, Litholink, US Labs, and CMBP
- **Share Results**
Email, fax, print and annotations make it easy to share critical information
- **Visual Cues**
Supports physician decision making, enhances the timeliness of patient care and facilitates follow-up with abnormal results in red and unread reports in bold




Results on the Go

- **Clear, Concise Reports**
Physicians and staff can quickly access results via iPhone® or iPad™ including alerts for abnormal or critical lab results
- **Connect to Patients**
Access patient demographics directly from results for phone or email follow up



Trends & Analytics

- **One-Click Trending**
Physicians and staff can quickly view a single test or analyte for one patient and the trended history for that patient
- **Sort and Filter Results**
Providers can filter their entire patient population on demographics and test results to identify trends and patients at risk
- **View Lab History**




AccuDraw Integration

- **Reduce Errors**
- **Reduce Training Time**
- **Proven Results**
Success in LabCorp Patient Service Centers will be extended to customers

Online Appointment Scheduling

- **Patient Convenience**
- **Improved Service Experience**
- **2011 Enhancements Will Improve Collections at the Time of Scheduling**



The screenshot displays the AccuDraw integration interface. At the top, it says "Collect in the following order:" and lists two items: a Blue Top (Sodium Citrate) tube with a quantity of 2.7 mL and a Serum Gel Tube with a quantity of 8.5 mL. Below this, there is a section for "To Collect" with a collection date of 12-02-2010 and a collection time of 02:52 PM. It also includes a "Print Guide" button. The main section is titled "To Submit" and contains a table with columns for QUANTITY, CONTAINER, PROCESSING INSTRUCTIONS, QUANTITY, Submit To Lab, and QUANTITY. The table lists three items: Blue Top (Sodium Citrate) (1.00 mL), Serum Gel Tube (2.60 mL), and Lavender Top (EDTA) (1.80 mL). At the bottom, there are buttons for "Cancel", "Save Order", and "Submit Order".

QUANTITY	CONTAINER	PROCESSING INSTRUCTIONS	QUANTITY	Submit To Lab	QUANTITY
1	Blue Top (Sodium Citrate)		1	1.00 mL Blue Top (Sodium Citrate)	1
1	Serum Gel Tube		1	2.60 mL Serum Gel Tube	1
1	Lavender Top (EDTA)		1	1.80 mL Lavender Top (EDTA)	1

**Continue to Improve
Efficiency to Offer the
Most Compelling Value
in Laboratory Services**



- Standardized lab and billing IT systems
- Automation of pre-analytics
- Supply chain optimization
- Sysmex fully automated hematology operations
- Consistent gross margin improvement (net of acquisitions)
- Full year bad debt reduction of 50bp in 2010



**Scientific Innovation
At Appropriate
Pricing**



- Introduction of new tests
- Acquisitions and licensing
- Collaborations with leading companies and academic institutions

Partner	Clinical Area
ARCA biopharma	Companion Diagnostics (Cardiovascular Disease)
BG Medicine	Cardiovascular Disease
Celera Diagnostics	Breast Cancer
Duke University	Joint Venture in biomarker development
Duke University	Lung Cancer
Exact Sciences	Colon Cancer
Intema Ltd.	Prenatal Testing
Johns Hopkins	Melanoma
MDxHealth	Companion Diagnostics (Oncology)
Medco Health Solutions	Companion Diagnostics (Research)
Merck	Companion Diagnostics (Infectious Disease)
On-Q-ity	Circulating tumor cells
University of Minnesota	Lupus
Veridex	Prostate Cancer
Yale University	Ovarian Cancer (exclusive)

- Recent offerings in companion diagnostics and personalized medicine
 - IL-28B
 - K-RAS
 - HLA-B* 5701
 - BRAF Gene Mutation Detection
 - EGFR Mutation Analysis
 - CYP 450 2C19
 - Trofile® (CCR5 Tropism)
 - PhenoSense®, PhenoSense GT®
 - HERmark®
- Outcome Improvement Programs
 - CKD program
 - Litholink kidney stone program
- Clearstone acquisition
 - Global clinical trials capability
 - Presence in China

“K-RAS testing should be routinely conducted in all colorectal cancer patients immediately after diagnosis to ensure the best treatment strategies for the individual Patient”

– Dr. Eric Van Cutsem, presenter at the June 2008 American Society of Clinical Oncology meeting

FDA recommends genetic screening prior to treatment with Abacavir

ROCKVILLE, Md -- July 24, 2008 -- The US Food and Drug Administration (FDA) has issued an alert regarding serious, and sometimes fatal, hypersensitivity reactions (HSRs) caused by abacavir (Ziagen) therapy in patients with a particular human leukocyte antigen (HLA) allele, HLA-B* 5701.

Genetic tests for HLA-B*5701 are already available, and all patients should be screened for the HLA-B*5701 allele before starting or restarting treatment with abacavir or abacavir-containing medications.

“FDA has approved the expanded use of Selzentry... to include adult patients with CCR5-tropic HIV-1 virus who are starting treatment for the first time.”

- ViiV Healthcare Press Release, November 20th, 2009


Alternative Delivery Models



Revenue and EPS Growth

- 6-year revenue CAGR of approximately 8.4%
- 6-year Adjusted EPS CAGR of approximately 14.6%

Revenue and Adjusted EPS Growth: 2004 – 2010 (1) (2)



(1) Excluding the \$0.09 per diluted share impact in 2005 of restructuring and other special charges, and a non-recurring investment loss; excluding the \$0.06 per diluted share impact in 2006 of restructuring and other special charges; excluding the \$0.25 per diluted share impact in 2007 of restructuring and other special charges; excluding the \$0.44 per diluted share impact in 2008 of restructuring and other special charges; excluding the (\$0.09) per diluted share impact in 2009 of restructuring and other special charges; excluding the (\$0.17) per diluted share impact in 2010 of restructuring and other special charges.

(2) EPS, as presented represents adjusted, non-GAAP financial measures. Diluted EPS, as reported in the Company's Annual Report were: \$2.45 in 2004; \$2.71 in 2005; \$3.24 in 2006; \$3.93 in 2007; \$4.26 in 2008; \$4.98 in 2009; and \$5.29 in 2010

Our Results

- Profitable revenue growth
 - Empire contract
 - Esoteric growth
 - Acquisitions
- Improved IT and client connectivity
 - LabCorp Beacon
 - Enhanced experience for physicians and patients
- Continued scientific leadership
 - Clearstone acquisition
 - IL-28B
 - New Monogram assays
- Maintained price
 - Managed care stability
 - Strong results



Second Quarter and First Half 2011 Results

	Three Months Ended Jun 30,			Six Months Ended Jun 30,		
	2011	2010	+/(-)	2011	2010	+/(-)
Revenue	\$ 1,403.3	\$ 1,238.4	13.3%	\$2,771.7	\$2,432.0	14.0%
Adjusted Operating Income ⁽¹⁾	\$ 279.6	\$ 270.5	3.4%	\$543.3	\$514.0	5.7%
Adjusted Operating Income Margin ⁽¹⁾	19.9%	21.8%	-190bp	19.6%	21.1%	-150bp
Adjusted EPS Excluding Amortization ⁽¹⁾	\$ 1.64	\$ 1.56	5.1%	\$3.18	\$2.96	7.4%
Operating Cash Flow	\$ 184.9	\$ 216.2	-14.5%	\$ 400.2	\$ 448.2	-10.7%
Less: Capital Expenditures	\$ (45.8)	\$ (34.5)	32.8%	\$ (75.2)	\$ (59.0)	27.5%
Free Cash Flow	\$ 139.1	\$ 181.7	-23.4%	\$ 325.0	\$ 389.2	-16.5%

(1) See Reconciliation of non-GAAP Financial Measures (included herein)

Note: During both the first quarter of 2010 and the first quarter of 2011, inclement weather reduced Adjusted EPS Excluding Amortization by approximately eight cents

Key Points

- Critical position in health care delivery system
- Attractive market
- Consistent strategy
 - Excellent cash flow deployed to enhance strong competitive position
 - IT innovation to improve physician and patient experience
 - Most efficient provider delivering greatest value
 - Scientific leadership
 - Alternative delivery models
- Track record of execution and success



Reconciliation of non-GAAP Financial Measures

Reconciliation of non-GAAP Financial Measures

(In millions, except per share data)

	Three Months Ended Jun 30,	
	2011	2010
<u>Adjusted Operating Income</u>		
Operating income	\$ 225.7	\$ 270.5
Restructuring and other special charges ^{(1) (2)}	53.9	-
Adjusted operating income	<u>\$ 279.6</u>	<u>\$ 270.5</u>
<u>Adjusted EPS Excluding Amortization</u>		
Diluted earnings per common share	\$ 1.20	\$ 1.46
Impact of restructuring and other special charges ^{(1) (2)}	0.32	-
Amortization expense	0.12	0.10
Adjusted EPS Excluding Amortization ⁽³⁾	<u>\$ 1.64</u>	<u>\$ 1.56</u>

1) During the second quarter of 2011, the Company recorded restructuring and other special charges of \$53.9 million. The restructuring charges include \$7.5 million in net severance and other personnel costs along with \$10.8 million in net facility-related costs primarily associated with the ongoing integration of the Genzyme Genetics and Westcliff acquisitions. The special charges also include \$34.5 million (\$49.5 million, net of previously recorded reserves of \$15.0 million) relating to the settlement of the Hunter Labs litigation, along with \$1.1 million for legal costs associated with the planned acquisition of Orchid Cellmark incurred during the quarter, both of which were recorded in Selling, General and Administrative Expenses in the Company's Statement of Operations. The after tax impact of these charges decreased net earnings for the quarter ended June 30, 2011, by \$32.6 million and diluted earnings per share by \$0.32 (\$32.6 million divided by 102.8 million shares).

During the first quarter of 2011, the Company recorded restructuring and other special charges of \$27.9 million. The charges included \$4.0 million in severance and other personnel costs along with \$9.8 million in facility-related costs associated with the integration of Genzyme Genetics. The charges also included a \$14.8 million write-off of an investment made in a prior year. For the six months ended June 30, 2011, the after tax impact of these combined charges decreased net earnings by \$49.4 million and diluted earnings per share by \$0.48 (\$49.4 million divided by 102.6 million shares).

2) During the first quarter of 2010, the Company recorded net charges of \$9.3 million relating to severance payments and the closing of redundant and underutilized facilities as well as the write-off of development costs incurred on systems abandoned during the quarter. The after tax impact of these charges decreased net earnings for the six months ended June 30, 2010, by \$5.7 million and diluted earnings per share by \$0.06 (\$5.7 million divided by 105.9 million shares).

3) The Company continues to grow its business through acquisitions and uses Adjusted EPS Excluding Amortization as a measure of operational performance, growth and shareholder returns. The Company believes adjusting EPS for amortization will provide investors with better insight into the operating performance of the business. For the quarters ended June 30, 2011 and 2010, intangible amortization was \$21.5 million and \$17.7 million, respectively (\$13.0 million and \$10.8 million net of tax, respectively) and decreased EPS by \$0.12 (\$13.0 million divided by 102.8 million shares) and \$0.10 (\$10.8 million divided by 105.9 million shares), respectively. For the six months ended June 30, 2011 and 2010, intangible amortization was \$43.4 million and \$35.1 million, respectively (\$26.5 million and \$21.5 million net of tax, respectively) and decreased EPS by \$0.26 (\$26.5 million divided by 102.6 million shares) and \$0.20 (\$21.5 million divided by 105.9 million shares), respectively.

Reconciliation of non-GAAP Financial Measures

Reconciliation of non-GAAP Financial Measures

(In millions, except per share data)

	Six Months Ended Jun 30,	
	2011	2010
<u>Adjusted Operating Income</u>		
Operating income	\$ 461.5	\$ 504.7
Restructuring and other special charges ^{(1) (2)}	81.8	9.3
Adjusted operating income	<u>\$ 543.3</u>	<u>\$ 514.0</u>
 <u>Adjusted EPS Excluding Amortization</u>		
Diluted earnings per common share	\$ 2.44	\$ 2.70
Impact of restructuring and other special charges ^{(1) (2)}	0.48	0.06
Amortization expense	0.26	0.20
Adjusted EPS Excluding Amortization ⁽³⁾	<u>\$ 3.18</u>	<u>\$ 2.96</u>

1) During the second quarter of 2011, the Company recorded restructuring and other special charges of \$53.9 million. The restructuring charges include \$7.5 million in net severance and other personnel costs along with \$10.8 million in net facility-related costs primarily associated with the ongoing integration of the Genzyme Genetics and Westcliff acquisitions. The special charges also include \$34.5 million (\$49.5 million, net of previously recorded reserves of \$15.0 million) relating to the settlement of the Hunter Labs litigation, along with \$1.1 million for legal costs associated with the planned acquisition of Orchid Cellmark incurred during the quarter, both of which were recorded in Selling, General and Administrative Expenses in the Company's Statement of Operations. The after tax impact of these charges decreased net earnings for the quarter ended June 30, 2011, by \$32.6 million and diluted earnings per share by \$0.32 (\$32.6 million divided by 102.8 million shares).

During the first quarter of 2011, the Company recorded restructuring and other special charges of \$27.9 million. The charges included \$4.0 million in severance and other personnel costs along with \$9.8 million in facility-related costs associated with the integration of Genzyme Genetics. The charges also included a \$14.8 million write-off of an investment made in a prior year. For the six months ended June 30, 2011, the after tax impact of these combined charges decreased net earnings by \$49.4 million and diluted earnings per share by \$0.48 (\$49.4 million divided by 102.6 million shares).

2) During the first quarter of 2010, the Company recorded net charges of \$9.3 million relating to severance payments and the closing of redundant and underutilized facilities as well as the write-off of development costs incurred on systems abandoned during the quarter. The after tax impact of these charges decreased net earnings for the six months ended June 30, 2010, by \$5.7 million and diluted earnings per share by \$0.06 (\$5.7 million divided by 105.9 million shares).

3) The Company continues to grow its business through acquisitions and uses Adjusted EPS Excluding Amortization as a measure of operational performance, growth and shareholder returns. The Company believes adjusting EPS for amortization will provide investors with better insight into the operating performance of the business. For the quarters ended June 30, 2011 and 2010, intangible amortization was \$21.5 million and \$17.7 million, respectively (\$13.0 million and \$10.8 million net of tax, respectively) and decreased EPS by \$0.12 (\$13.0 million divided by 102.8 million shares) and \$0.10 (\$10.8 million divided by 105.9 million shares), respectively. For the six months ended June 30, 2011 and 2010, intangible amortization was \$43.4 million and \$35.1 million, respectively (\$26.5 million and \$21.5 million net of tax, respectively) and decreased EPS by \$0.26 (\$26.5 million divided by 102.6 million shares) and \$0.20 (\$21.5 million divided by 105.9 million shares), respectively.

Supplemental Financial Information

Laboratory Corporation of America Other Financial Information FY 2009, FY 2010 and Q1-Q2 2011

	<u>Q1 09</u>	<u>Q2 09</u>	<u>Q3 09</u>	<u>Q4 09</u>	<u>Q1 10</u>	<u>Q2 10</u>	<u>Q3 10</u>	<u>Q4 10</u>	<u>Q1 11</u>	<u>Q2 11</u>
Bad debt as a percentage of sales	5.3%	5.3%	5.3%	5.3%	5.0%	4.8%	4.8%	4.7%	4.7%	4.7%
Days sales outstanding ¹	52	50	48	44	46	45	44	46	47	46
A/R coverage (Allow. for Doubtful Accts. / A/R) ²	19.5%	20.6%	21.9%	23.2%	21.7%	20.7%	20.4%	18.5%	19.4%	20.6%

(1) Excluding the impact from Genzyme Genetics, DSO was 43 days in Q4 of 2010, 45 days in Q1 of 2011 and 43 days in Q2 of 2011

(2) Excluding the impact from Genzyme Genetics, A/R Coverage was 19.9% in Q4 of 2010, 20.4% in Q1 of 2011 and 21.1% in Q2 of 2011

